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The second edition of the ‘Oxford Textbook of Oncology’, edited
by Souhami, Tannock, Hohenberger and Horiot, is a well
presented, thorough review of the ﬁeld of oncology. The book is
interdisciplinary with important contributions from medical, surgi-
cal, and radiation oncologists. Although the two volumes make it
somewhat less convenient to use, the material is not difﬁcult to
ﬁnd, and the chapters are generally well written.
This is a largely European text. It is more comprehensive than
the ‘Textbook of Medical Oncology’ by Cavalli, Hansen, and
Kay, although that text is well-written and easy to use. The ‘Oxford
Textbook of Oncology’ deals with subjects in more depth and is
more likely to yield an unusual fact about a particular cancer.
The 2nd edition of the ‘Oxford Textbook of Oncology’ is in
many ways like two major American texts – ‘Cancer, Principles
and Practices of Oncology’ by DeVita, Hellman and Rosenberg,
and ‘Clinical Oncology’ by Abelhoff, Armitage, Lichter, and
Niederhuber. Table 1 compares and contrasts several aspects of
these texts.
These three texts are all similar in length. The DeVita textbook
is the most extensively indexed and the Souhami text the least
extensively indexed. The Abelhoff text has more emphasis on biol-
ogy than either DeVita or Souhami. The Souhami text deals less
with prevention but much more with the principles of the various
therapeutic modalities. However, it deals less with the clinical
problems associated with cancer and metastasis.
The varying emphasis on the different malignancies among these
texts reﬂected in the length of the disease speciﬁc chapters is inter-
esting. It is uncertain whether this represents a different emphasis
of the editors, or simply a proclivity to long chapters by certain of
the authors. Either way, head and neck cancer is much more exten-
sively dealt with in the Souhami text than in the other two, and
pediatrics less in the DeVita text. In many areas (e.g. lymphoma,
lung cancer, and breast cancer), similar proportions of the books
are devoted to the topic.
One problem with any oncology text is the difﬁculty in incor-
porating new advances. For example, imatinib mesylate has
become the treatment of choice for chronic myeloid leukemia
and unresectable gastrointestinal stromal sarcomas. However,
the drug is dealt with very brieﬂy in the chronic myeloid leuke-
mia chapter and not at all in the sections on gastrointestinal
stromal sarcomas. Also, one of the most important new techni-
ques in classifying, deﬁning prognostic groups and, eventually,
developing new treatments is likely to be the use of gene arrays.
This topic is addressed brieﬂy in the chapter on genetics and not
at all in the chapters on the diseases where it is likely to be soon
applied in the clinic. This is to some degree an unavoidable
problem and one that will certainly be dealt with in future
editions.
In summary, Souhami et al have produced a high quality text-
book of oncology. By owning all three of the major texts, there
would be very few facts one could not ﬁnd. However, these are
all excellent resources.
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Table 1
Number of pages (% of text)
Oxford... Cancer... Clinical Onc...
Souhami DeVita Abelhoff
Length 2851 3235 2865
Index 64 164 96
Biology 126 (4%) 149 (5%) 279 (10%)
Etiology/Epidemiology 74 (2½%) 109 (3%) 62 (2%)
Prevention 12 (½%) 78 (2½%) 48 (2%)
Principles of treatment 540 (19%) 321 (10%) 116 (4%)
Complications of cancer 148 (5%) 394 (12%) 489 (17%)
Melanoma 58 (2%) 88 (3%) 34 (1%)
Head & neck 224 (8%) 128 (4%) 69 (2½%)
Gastrointestinal 200 (7%) 306 (9½%) 267 (9%)
Breast 106 (4%) 94 (3%) 109 (4%)
Gynecology 150 (5%) 114 (3½%) 95 (3%)
Prostate 34 (1%) 62 (2%) 62 (2%)
Lung 58 (2%) 102 (3%) 80 (3%)
Hodgkins disease/lymphoma 136 (5%) 164 (5%) 151 (5%)
Pediatrics 108 (4%) 54 (1½%) 95 (3%)
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